Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Revenue (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Revenue for 11 consecutive years, with $59366.0 as the latest value for Q3 2025.

  • On a quarterly basis, Revenue changed 0.0% to $59366.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $177496.0, a 15.13% decrease, with the full-year FY2025 number at $236561.0, changed 0.0% from a year prior.
  • Revenue was $59366.0 for Q3 2025 at Regen BioPharma, up from $59065.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $141640.0 in Q3 2023 to a low of -$1.8 million in Q3 2021.
  • A 5-year average of -$44298.7 and a median of $59065.0 in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: plummeted 6650.1% in 2021, then soared 138.59% in 2023.
  • Regen BioPharma's Revenue stood at $31640.0 in 2021, then changed by 0.0% to $31640.0 in 2022, then skyrocketed by 86.68% to $59065.0 in 2023, then changed by 0.0% to $59065.0 in 2024, then grew by 0.51% to $59366.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Revenue are $59366.0 (Q3 2025), $59065.0 (Q2 2025), and $59065.0 (Q1 2025).